ArticleBrain, behavior, & immunity - health2026
Transcriptomic analysis reveals synaptic dysregulation and mitochondrial dysfunction in autism spectrum disorder.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the molecular relationship between mitochondrial dysfunction and synaptic dysregulation in autism spectrum disorder (ASD) through transcriptomic analysis, focusing on gene expression changes and disrupted pathways related to synaptic abnormalities and metabolic disruption. Methods: Transcriptomic data from peripheral blood samples in the GSE18123 dataset were analyzed to identify transcriptional changes associated with ASD. The analysis focused on 1205 neurodevelopmental genes, with differential expression analysis conducted to compare gene expression between ASD and neurotypical control (NC) groups. Functional enrichment analyses using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways mapped disrupted biological processes. Protein-protein interaction (PPI) networks were constructed to highlight central regulatory hubs, while gene co-expression analyses were employed to examine coordinated dysregulation across synaptic and metabolic networks. Results: A total of 27 differentially expressed genes were identified, with 22 showing upregulation, suggesting increased molecular activity. Enrichment analyses highlighted the dysregulation of synaptic signaling pathways and mitochondrial oxidative phosphorylation, revealing a mechanistic link between metabolism disruption and synaptic abnormalities. PPI network analysis identified central regulatory hubs, including DKK1 and CYCS, highlighting intricate interactions between synaptic and mitochondrial pathways. Co-expression analysis demonstrated correlations within metabolic and synaptic functional modules, indicative of coordinated transcriptional dysregulation in ASD. Conclusion: This analysis uncovers a distinct molecular signature in ASD, emphasizing the convergence of synaptic abnormalities and metabolic disruption. The findings provide valuable insights into the pathophysiology of ASD and highlight potential targets for biomarker development and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.